PHAROS regimen shows major gain for lung cancer patients | The Jerusalem PostJerusalem Post/Health & WellnessFirst-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data…
PHAROS regimen shows major gain for lung cancer patients
